Health and Healthcare
5864 Articles
Usually when you see stocks double, it is based on a buyout or a major partnership development. That is not…
Jon OggCytRx Corporation (NASDAQ: CYTR) saw its shares get punished on Friday for a secondary offering. Frankly, the pricing of…
Six IPOs hit the market Friday , and three of them were biotechs. What stands out is that these emerging…
Biogen Idec surprised investors Wednesday with weaker-than-expected guidance for 2014 earnings. Amgen beat estimates late Tuesday. Celgene and Gilead Sciences…
Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large…
ThinkstockAmgen Inc. (NASDAQ: AMGN) is the second largest biotech player, and now we have seen its fourth-quarter earnings report. Earnings…
Pfizer has managed to handily beat consensus fourth-quarter earnings expectations, at least on the surface. It also offered guidance for…
Analysts at at Merrill Lynch see 2014 as a promising year for biotech mergers and acquisitions. A new research report…
Once again, the analysts at Piper Jaffray are conducting extensive management meetings with the companies they cover. Here are the…
Ariad Pharmaceuticals could be joining the ranks of the next big biotech acquisitions. The company fits the bill of many…
ThinkstockThermoGenesis Corp. (NASDAQ: KOOL) is seeing a day-two run in its stock, but investors might want to pay close attention…
Here are some of the top biotech names to buy at Cowen. They presented such an extensive list that we…
Teva Pharmaceutical resume a deal-making strategy that made it one of the most acquisitive drug companies of the past decade.…
The analysts at Piper Jaffray have returned from meeting with some of the top biotechs the cover, and they have…
Before markets opened Thursday morning, UnitedHealth Group reported fourth-quarter and full-year 2013 results that topped consensus estimates on the top…
Our top personal finance-related articles today. Your wallet will thank you later.